| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Juliana Minardi Nascimento | Q37368289 |
| Daniel Martins-de-Souza | Q28678599 | ||
| P2860 | cites work | Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis | Q21144689 |
| Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation | Q21260256 | ||
| Disrupted-in-schizophrenia 1 (DISC1) plays essential roles in mitochondria in collaboration with Mitofilin | Q24301405 | ||
| Biological insights from 108 schizophrenia-associated genetic loci | Q24561833 | ||
| High resolution two-dimensional electrophoresis of proteins | Q24608190 | ||
| Common variants conferring risk of schizophrenia | Q24614376 | ||
| Modelling schizophrenia using human induced pluripotent stem cells | Q24633007 | ||
| Genome-scale neurogenetics: methodology and meaning | Q26859474 | ||
| Induction of pluripotent stem cells from adult human fibroblasts by defined factors | Q27860967 | ||
| Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics | Q28131742 | ||
| Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex | Q28138248 | ||
| Genome-wide association study identifies five new schizophrenia loci | Q28248384 | ||
| Common polygenic variation contributes to risk of schizophrenia and bipolar disorder | Q28250609 | ||
| Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues | Q28253419 | ||
| A first step toward completion of a genome-wide characterization of the human proteome | Q45740688 | ||
| Quantitative profiling of proteins in complex mixtures using liquid chromatography and mass spectrometry. | Q45997049 | ||
| A comparative proteomics analysis of rat mitochondria from the cerebral cortex and hippocampus in response to antipsychotic medications. | Q46012495 | ||
| Targeted proteomics | Q46143284 | ||
| 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease | Q46661063 | ||
| Label-free quantitative proteomic analysis reveals dysfunction of complement pathway in peripheral blood of schizophrenia patients: evidence for the immune hypothesis of schizophrenia. | Q47383429 | ||
| Mitochondrial complex I subunits expression is altered in schizophrenia: a postmortem study | Q47900194 | ||
| 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia | Q48319021 | ||
| Quintessence from proteomics networks--the HUPO Brain Proteome Project Pilot Studies | Q48422993 | ||
| Protein phosphorylation patterns in serum from schizophrenia patients and healthy controls | Q48526200 | ||
| Global proteomic profiling reveals altered proteomic signature in schizophrenia serum | Q48536502 | ||
| A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia | Q48642132 | ||
| Proteomic and genomic evidence implicates the postsynaptic density in schizophrenia | Q48646111 | ||
| Anterior hippocampus in schizophrenia pathogenesis: molecular evidence from a proteome study | Q48698691 | ||
| Altered oxygen metabolism associated to neurogenesis of induced pluripotent stem cells derived from a schizophrenic patient | Q48860052 | ||
| Proteomic approaches to unravel the complexity of schizophrenia | Q37980246 | ||
| Proteomic analysis of cell fate decision | Q38128685 | ||
| The role of anti-inflammatory treatment in psychiatric disorders. | Q38139245 | ||
| Next-generation sequencing in schizophrenia and other neuropsychiatric disorders | Q38153345 | ||
| The use of proteomic biomarkers for improved diagnosis and stratification of schizophrenia patients | Q38170139 | ||
| Myelination and oligodendrocyte functions in psychiatric diseases | Q38199654 | ||
| 2DE: the phoenix of proteomics. | Q38202467 | ||
| The synapse in schizophrenia | Q38203024 | ||
| The emergence of proteome-wide technologies: systematic analysis of proteins comes of age. | Q38221025 | ||
| Modeling hippocampal neurogenesis using human pluripotent stem cells | Q38460557 | ||
| MIR137 variants identified in psychiatric patients affect synaptogenesis and neuronal transmission gene sets | Q38989183 | ||
| Cytokine alterations in first-episode schizophrenia patients before and after antipsychotic treatment | Q39242341 | ||
| Perturbation in mitochondrial network dynamics and in complex I dependent cellular respiration in schizophrenia | Q39577276 | ||
| Metabolic, hormonal and stress-related molecular changes in post-mortem pituitary glands from schizophrenia subjects | Q39664112 | ||
| Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. | Q39791733 | ||
| Mitochondrial complex I as a novel target for intraneuronal DA: modulation of respiration in intact cells | Q39850480 | ||
| Expression profiling of fibroblasts identifies cell cycle abnormalities in schizophrenia | Q39928887 | ||
| Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia | Q40834916 | ||
| Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it. | Q41248468 | ||
| Synaptic dysregulation in a human iPS cell model of mental disorders | Q41534293 | ||
| Proteomics tackling schizophrenia as a pathway disorder. | Q42352224 | ||
| Activation of brain interleukin-1beta in schizophrenia. | Q42852301 | ||
| Proteome analysis of the thalamus and cerebrospinal fluid reveals glycolysis dysfunction and potential biomarkers candidates for schizophrenia | Q43062918 | ||
| Different apolipoprotein E, apolipoprotein A1 and prostaglandin-H2 D-isomerase levels in cerebrospinal fluid of schizophrenia patients and healthy controls | Q43072099 | ||
| Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naïve schizophrenia patients | Q43185085 | ||
| Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. | Q43940200 | ||
| Targeted proteomics for validation of biomarkers in early psychosis | Q44138872 | ||
| Identification and validation of platelet low biological variation proteins, superior to GAPDH, actin and tubulin, as tools in clinical proteomics. | Q44773945 | ||
| Distinct cerebrospinal fluid amyloid-beta peptide signatures in cognitive decline associated with Alzheimer's disease and schizophrenia. | Q45420612 | ||
| Perspective: Revealing molecular secrets. | Q50651034 | ||
| Quantification of Proteins by Label-Free LC-MS/MS | Q51661501 | ||
| The human proteome project: Current state and future direction. | Q51711697 | ||
| Using our brains: the findings, flaws, and future of postmortem studies of psychiatric disorders. | Q51770691 | ||
| Characterization of salivary proteins of schizophrenic and bipolar disorder patients by top-down proteomics. | Q53059728 | ||
| iTRAQ and multiple reaction monitoring as proteomic tools for biomarker search in cerebrospinal fluid of patients with Parkinson's disease dementia. | Q54530327 | ||
| The Chromosome-Centric Human Proteome Project for cataloging proteins encoded in the genome. | Q55055789 | ||
| Isoelectric focusing in immobilized pH gradients: Principle, methodology and some applications | Q56032045 | ||
| S100B is downregulated in the nuclear proteome of schizophrenia corpus callosum | Q59791401 | ||
| Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder | Q60440984 | ||
| Identification of a biological signature for schizophrenia in serum | Q60649874 | ||
| Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients | Q60649880 | ||
| Approach to stationary two-dimensional pattern: influence of focusing time and immobiline/carrier ampholytes concentrations | Q69057084 | ||
| Schizophrenia | Q79226206 | ||
| Impaired glucose tolerance in first-episode drug-naïve patients with schizophrenia | Q80024902 | ||
| Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study | Q82774054 | ||
| Identification of a blood-based biological signature in subjects with psychiatric disorders prior to clinical manifestation | Q84971446 | ||
| Biomarkers in schizophrenia | Q86928194 | ||
| Talking back to madness | Q87437638 | ||
| Insights into the regulation of protein abundance from proteomic and transcriptomic analyses | Q36846022 | ||
| Selected reaction monitoring for quantitative proteomics: a tutorial | Q36973024 | ||
| Proteomic analysis of eccrine sweat: implications for the discovery of schizophrenia biomarker proteins | Q36989604 | ||
| Proteomic profiling in schizophrenia: enabling stratification for more effective treatment | Q36998471 | ||
| A combined metabonomic and proteomic approach identifies frontal cortex changes in a chronic phencyclidine rat model in relation to human schizophrenia brain pathology | Q37235856 | ||
| Redox dysregulation, neurodevelopment, and schizophrenia | Q37501168 | ||
| Proteome and transcriptome analysis suggests oligodendrocyte dysfunction in schizophrenia | Q37584569 | ||
| The audacity of proteomics: a chance to overcome current challenges in schizophrenia research | Q37636121 | ||
| Proteome analysis of schizophrenia brain tissue | Q37682924 | ||
| The role of energy metabolism dysfunction and oxidative stress in schizophrenia revealed by proteomics | Q37776737 | ||
| The neuroproteomics of schizophrenia. | Q37796059 | ||
| Sub-proteome approach to the knowledge of liver | Q37817300 | ||
| After GWAS: searching for genetic risk for schizophrenia and bipolar disorder. | Q37834132 | ||
| The genetic architecture of schizophrenia: new mutations and emerging paradigms | Q37950402 | ||
| Proteomic technologies for biomarker studies in psychiatry: advances and needs | Q37952388 | ||
| Antipsychotics in the treatment of schizophrenia: an overview | Q37973145 | ||
| Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress | Q28257571 | ||
| Difference gel electrophoresis: a single gel method for detecting changes in protein extracts | Q28258266 | ||
| Effectiveness of antipsychotic drugs in patients with chronic schizophrenia | Q28273164 | ||
| Genome-wide association analysis identifies 13 new risk loci for schizophrenia | Q28297287 | ||
| DISC1 complexes with TRAK1 and Miro1 to modulate anterograde axonal mitochondrial trafficking | Q28299770 | ||
| A framework for interpreting genome-wide association studies of psychiatric disorders | Q28300576 | ||
| CSF metabolic and proteomic profiles in patients prodromal for psychosis | Q28469277 | ||
| Disrupted-In-Schizophrenia 1 regulates integration of newly generated neurons in the adult brain | Q28507787 | ||
| The role of genetics in the etiology of schizophrenia | Q28748800 | ||
| Cerebral organoids model human brain development and microcephaly | Q28973619 | ||
| Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents | Q29547450 | ||
| Mass-spectrometry-based draft of the human proteome | Q29617249 | ||
| A draft map of the human proteome | Q29617250 | ||
| Direct analysis of protein complexes using mass spectrometry | Q29617450 | ||
| Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia | Q30447546 | ||
| Identification of proteomic signatures associated with depression and psychotic depression in post-mortem brains from major depression patients | Q30468799 | ||
| Review of pathological hallmarks of schizophrenia: comparison of genetic models with patients and nongenetic models | Q30476810 | ||
| Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients | Q30511886 | ||
| Myelination, oligodendrocytes, and serious mental illness | Q30838265 | ||
| Plasma protein biomarkers for depression and schizophrenia by multi analyte profiling of case-control collections | Q30977897 | ||
| Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. | Q33319373 | ||
| De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. | Q33398247 | ||
| Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways | Q33762512 | ||
| Differential proteomic analysis of mammalian tissues using SILAM. | Q33809263 | ||
| Common proteomic changes in the hippocampus in schizophrenia and bipolar disorder and particular evidence for involvement of cornu ammonis regions 2 and 3. | Q33887879 | ||
| Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium | Q33902752 | ||
| Twin studies of schizophrenia: from bow-and-arrow concordances to star wars Mx and functional genomics | Q33920482 | ||
| Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia | Q33941953 | ||
| Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders | Q33945211 | ||
| Genetic architectures of psychiatric disorders: the emerging picture and its implications | Q33949729 | ||
| Impaired metabolic reactivity to oxidative stress in early psychosis patients | Q34048645 | ||
| A polygenic burden of rare disruptive mutations in schizophrenia | Q34060200 | ||
| Sex-specific proteome differences in the anterior cingulate cortex of schizophrenia | Q34109438 | ||
| Catching up on schizophrenia: natural history and neurobiology | Q34122141 | ||
| Genome-wide association study of major depressive disorder: new results, meta-analysis, and lessons learned | Q34147518 | ||
| The application of selective reaction monitoring confirms dysregulation of glycolysis in a preclinical model of schizophrenia | Q34197032 | ||
| Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials | Q34205157 | ||
| Proteomic analysis identifies dysfunction in cellular transport, energy, and protein metabolism in different brain regions of atypical frontotemporal lobar degeneration | Q34256510 | ||
| Selected reaction monitoring-based proteomics: workflows, potential, pitfalls and future directions | Q34279143 | ||
| Analyzing schizophrenia by DNA microarrays | Q34367499 | ||
| Neural development, cell-cell signaling, and the "two-hit" hypothesis of schizophrenia | Q34398952 | ||
| Mass spectrometry in proteomics | Q34441839 | ||
| Quantitative mass spectrometric multiple reaction monitoring assays for major plasma proteins | Q34473545 | ||
| Oxidative stress in schizophrenia: An integrated approach | Q34494844 | ||
| RNA-Seq analysis implicates dysregulation of the immune system in schizophrenia | Q34530641 | ||
| De novo mutations in schizophrenia implicate synaptic networks | Q34540372 | ||
| The genetics of schizophrenia and bipolar disorder: dissecting psychosis | Q34555635 | ||
| The nature of systems biology | Q34582744 | ||
| Alterations in oligodendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis | Q34888915 | ||
| Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. | Q34911118 | ||
| Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia | Q34928687 | ||
| Deciphering the human brain proteome: characterization of the anterior temporal lobe and corpus callosum as part of the Chromosome 15-centric Human Proteome Project | Q35052619 | ||
| Transcriptome sequencing and genome-wide association analyses reveal lysosomal function and actin cytoskeleton remodeling in schizophrenia and bipolar disorder | Q35079675 | ||
| Multiplatform metabolome and proteome profiling identifies serum metabolite and protein signatures as prospective biomarkers for schizophrenia. | Q35162008 | ||
| Dopamine receptor-interacting proteins: the Ca(2+) connection in dopamine signaling. | Q35216451 | ||
| A high-confidence human plasma proteome reference set with estimated concentrations in PeptideAtlas | Q35264564 | ||
| Quantitative proteomic and genetic analyses of the schizophrenia susceptibility factor dysbindin identify novel roles of the biogenesis of lysosome-related organelles complex 1. | Q35856391 | ||
| Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. | Q36148572 | ||
| Exome sequencing followed by large-scale genotyping suggests a limited role for moderately rare risk factors of strong effect in schizophrenia | Q36152879 | ||
| Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function | Q36377477 | ||
| Critical appraisal of DNA microarrays in psychiatric genomics. | Q36450259 | ||
| Biochemical fractionation and stable isotope dilution liquid chromatography-mass spectrometry for targeted and microdomain-specific protein quantification in human postmortem brain tissue | Q36455717 | ||
| Interpreting the protein language using proteomics. | Q36488705 | ||
| DISC1 genetics, biology and psychiatric illness | Q36634401 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International | Q24082749 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | schizophrenia | Q41112 |
| P304 | page(s) | 14003 | |
| P577 | publication date | 2015-03-04 | |
| P1433 | published in | NPJ schizophrenia | Q27726482 |
| P1476 | title | The proteome of schizophrenia | |
| P478 | volume | 1 |
| Q36020336 | A reference library of peripheral blood mononuclear cells for SWATH-MS analysis |
| Q50054678 | Altered Expression Profile of IgLON Family of Neural Cell Adhesion Molecules in the Dorsolateral Prefrontal Cortex of Schizophrenic Patients |
| Q47763221 | Combining Patient-Reprogrammed Neural Cells and Proteomics as a Model to Study Psychiatric Disorders. |
| Q90069138 | Computational chemoproteomics to understand the role of selected psychoactives in treating mental health indications |
| Q38869531 | Connecting Brain Proteomics with Behavioural Neuroscience in Translational Animal Models of Neuropsychiatric Disorders. |
| Q51298241 | Depletion of Highly Abundant Proteins of the Human Blood Plasma: Applications in Proteomics Studies of Psychiatric Disorders. |
| Q91942111 | Dystrophy of Oligodendrocytes and Adjacent Microglia in Prefrontal Gray Matter in Schizophrenia |
| Q30388470 | Effect of MK-801 and Clozapine on the Proteome of Cultured Human Oligodendrocytes |
| Q38985869 | Epigenetic Treatment of Persistent Viral Infections. |
| Q31049198 | Integrative Analysis of Multi-omics Data for Discovery and Functional Studies of Complex Human Diseases |
| Q46143080 | Key players in neurodegenerative disorders in focus-New insights into the proteomic profile of Alzheimer's disease, schizophrenia, ALS, and multiple sclerosis-24th HUPO BPP Workshop: September 29, 2015, Vancouver, Canada |
| Q92188482 | Kininogen-1 as a protein biomarker for schizophrenia through mass spectrometry and genetic association analyses |
| Q26771434 | Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research |
| Q28078375 | Mass Spectrometry-Based Approaches to Understand the Molecular Basis of Memory |
| Q91619653 | Mitochondrial Dysfunction and Changes in High-Energy Compounds in Different Cellular Models Associated to Hypoxia: Implication to Schizophrenia |
| Q35880985 | Molecular Signatures of Psychosocial Stress and Cognition Are Modulated by Chronic Lithium Treatment |
| Q98205070 | Molecular linkage between post-traumatic stress disorder and cognitive impairment: a targeted proteomics study of World Trade Center responders |
| Q52372478 | New considerations for hiPSC-based models of neuropsychiatric disorders. |
| Q89983282 | Post-translational protein modifications in schizophrenia |
| Q47763202 | Preparation of Peripheral Blood Mononuclear Cells (PBMCs) as a Model for Proteomic Studies of Psychiatric Disorders |
| Q26766821 | Proteomics Research in Schizophrenia |
| Q38903697 | Proteomics and molecular tools for unveiling missing links in the biochemical understanding of schizophrenia |
| Q57169146 | Proteomics for blood biomarker exploration of severe mental illness: pitfalls of the past and potential for the future |
| Q92070536 | Proteomics in Schizophrenia: A Gateway to Discover Potential Biomarkers of Psychoneuroimmune Pathways |
| Q47688592 | Proteomics in the Diagnosis of Inborn Encephalopathies of Unknown Origin: A Myth or Reality |
| Q40671746 | Proteomics of the corpus callosum unravel pivotal players in the dysfunction of cell signaling, structure, and myelination in schizophrenia brains |
| Q91757366 | Salivary Flow Alteration in Patients Undergoing Treatment for Schizophrenia: Disease-Drug-Target Gene/Protein Association Study for Side-effects |
| Q34531777 | Schizophrenia interactome with 504 novel protein-protein interactions |
| Q48239735 | Selective Reaction Monitoring Mass Spectrometry for Quantitation of Glycolytic Enzymes in Postmortem Brain Samples. |
| Q41286620 | The Energy Metabolism Dysfunction in Psychiatric Disorders Postmortem Brains: Focus on Proteomic Evidence |
| Q99238089 | The Gut Microbiome in Psychosis From Mice to Men: A Systematic Review of Preclinical and Clinical Studies |
| Q47844652 | The Nuclear Proteome of White and Gray Matter from Schizophrenia Postmortem Brains |
| Q60045096 | Ultrastructural pathology of oligodendrocytes adjacent to microglia in prefrontal white matter in schizophrenia |
Search more.